Works matching AU Chon, Hong Jae
Results: 49
Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
- Published in:
- 2019
- By:
- Publication type:
- journal article
High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
- Published in:
- Journal of Cancer, 2023, v. 14, n. 6, p. 935, doi. 10.7150/jca.81384
- By:
- Publication type:
- Article
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 5, p. 1335, doi. 10.3390/jcm13051335
- By:
- Publication type:
- Article
Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920923424
- By:
- Publication type:
- Article
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919871126
- By:
- Publication type:
- Article
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919871126
- By:
- Publication type:
- Article
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
- Published in:
- Experimental & Molecular Medicine EMM, 2020, p. 1475, doi. 10.1038/s12276-020-00500-y
- By:
- Publication type:
- Article
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 3, p. 2731, doi. 10.1002/cam4.5161
- By:
- Publication type:
- Article
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 5, p. 995, doi. 10.1002/cncr.34019
- By:
- Publication type:
- Article
The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.
- Published in:
- Gastric Cancer, 2019, v. 22, n. 1, p. 113, doi. 10.1007/s10120-018-0847-5
- By:
- Publication type:
- Article
Robotic transduodenal ampullectomy: A novel minimally invasive approach for ampullary neoplasms.
- Published in:
- International Journal of Medical Robotics & Computer Assisted Surgery, 2019, v. 15, n. 3, p. N.PAG, doi. 10.1002/rcs.1979
- By:
- Publication type:
- Article
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
- Published in:
- Liver International, 2024, v. 44, n. 8, p. 1961, doi. 10.1111/liv.15935
- By:
- Publication type:
- Article
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
- Published in:
- Liver International, 2022, v. 42, n. 3, p. 674, doi. 10.1111/liv.15102
- By:
- Publication type:
- Article
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study.
- Published in:
- Liver International, 2020, v. 40, n. 10, p. 2544, doi. 10.1111/liv.14573
- By:
- Publication type:
- Article
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7565, doi. 10.1007/s00432-023-04678-2
- By:
- Publication type:
- Article
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5591, doi. 10.1007/s00432-022-04512-1
- By:
- Publication type:
- Article
Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma.
- Published in:
- APMIS, 2017, v. 125, n. 3, p. 223, doi. 10.1111/apm.12656
- By:
- Publication type:
- Article
Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 17, p. 9414, doi. 10.3390/ijms22179414
- By:
- Publication type:
- Article
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 15, p. 8035, doi. 10.3390/ijms22158035
- By:
- Publication type:
- Article
Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 20, p. 7743, doi. 10.3390/ijms21207743
- By:
- Publication type:
- Article
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer.
- Published in:
- BMC Cancer, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2407-13-394
- By:
- Publication type:
- Article
A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 5, p. 522, doi. 10.1159/000537915
- By:
- Publication type:
- Article
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 1, p. 89, doi. 10.1159/000531182
- By:
- Publication type:
- Article
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 5, p. 613, doi. 10.1159/000508901
- By:
- Publication type:
- Article
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”.
- Published in:
- Clinical & Molecular Hepatology, 2025, v. 31, n. 1, p. e98, doi. 10.3350/cmh.2024.0916
- By:
- Publication type:
- Article
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 4, p. 1005, doi. 10.3350/cmh.2024.0394
- By:
- Publication type:
- Article
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 3, p. 345, doi. 10.3350/cmh.2023.0553
- By:
- Publication type:
- Article
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year.
- Published in:
- Cancer Research & Treatment, 2024, v. 56, n. 4, p. 1231, doi. 10.4143/crt.2024.237
- By:
- Publication type:
- Article
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 4, p. 1291, doi. 10.4143/crt.2022.1450
- By:
- Publication type:
- Article
Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer.
- Published in:
- Cancer Research & Treatment, 2017, v. 49, n. 4, p. 1127, doi. 10.4143/crt.2016.538
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359221148541
- By:
- Publication type:
- Article
The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221113266
- By:
- Publication type:
- Article
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221097934
- By:
- Publication type:
- Article
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211035983
- By:
- Publication type:
- Article
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211035983
- By:
- Publication type:
- Article
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5985, doi. 10.3390/cancers14235985
- By:
- Publication type:
- Article
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133213
- By:
- Publication type:
- Article
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1747, doi. 10.3390/cancers14071747
- By:
- Publication type:
- Article
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4906, doi. 10.3390/cancers13194906
- By:
- Publication type:
- Article
Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3123, doi. 10.3390/cancers12113123
- By:
- Publication type:
- Article
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 6, p. 1043, doi. 10.1002/ijc.34799
- By:
- Publication type:
- Article
Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy.
- Published in:
- Gut & Liver, 2024, v. 18, n. 6, p. 1085, doi. 10.5009/gnl240087
- By:
- Publication type:
- Article
Systemic Delivery of a STING Agonist‐Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis (Small 43/2023).
- Published in:
- Small, 2023, v. 19, n. 43, p. 1, doi. 10.1002/smll.202370353
- By:
- Publication type:
- Article
Systemic Delivery of a STING Agonist‐Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
- Published in:
- Small, 2023, v. 19, n. 43, p. 1, doi. 10.1002/smll.202300544
- By:
- Publication type:
- Article
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
- Published in:
- Targeted Oncology, 2023, v. 18, n. 2, p. 221, doi. 10.1007/s11523-023-00953-x
- By:
- Publication type:
- Article